Physician profile
Amber Sobuto
NPI 1124361977
$3,180.22
in general payments reported to CMS, 2019-2025
42 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $114 · 2022: $328 · 2023: $420 · 2024: $662 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.73 |
| Education | $131.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $280.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $262.82 | 2019-2025 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.53 | 2019-2024 | |
| Seagen INC. | $164.31 | 2019-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $159.03 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Celgene Corporation | $156.83 | 2019-2023 | Pomalyst |
| Jazz Pharmaceuticals INC. | $149.66 | 2022 | |
| Janssen Biotech, INC. | $145.33 | 2019-2025 | Erleada, Talvey, Tecvayli |
| Genentech USA, INC. | $143.14 | 2019-2025 | Venclexta, Rozlytrek, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $132.23 | 2019-2025 | |
| Sobi, INC | $122.42 | 2022-2024 | |
| Amgen INC. | $102.78 | 2019-2024 | Blincyto, Kyprolis, Vectibix |
| Abbvie INC. | $101.18 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $101.09 | 2019-2024 | |
| Lilly USA, LLC | $87.42 | 2019-2023 | Verzenio, Jaypirca |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Sobuto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.